Introduction
Uterine leiomyomas, or fibroids, are the most common tumors of the female reproductive tract clinically affecting , 30% of reproductive aged women in the USA (Buttram and Reiter, 1981) with an estimated cumulative incidence as high as 70 -80% by age 50 (Cramer and Patel, 1990; Baird et al., 2003) . Symptoms attributable to fibroids involve pelvic pressure and pain, abnormal uterine bleeding, and reproductive dysfunction, including reduced fertility or pregnancy complications (Coronado et al., 2000) . Uterine fibroids are the leading reason for hysterectomy among US women accounting for one-third of , 600 000 procedures performed annually (Farquhar and Steiner, 2002) .
Despite this major impact on gynaecological morbidity, the aetiology of uterine leiomyoma remains poorly understood. Epidemiological studies suggest that risk is inversely associated with parity, age at menarche, and age at menopause, whereas obesity, late reproductive age, and nulliparity are associated with increased risk (Flake et al., 2003) .
A genetic basis of uterine leiomyoma is suggested by several lines of evidence. Compared to other ethnic groups, women of African-American descent are at higher risk of uterine fibroids, which develop at earlier ages, and tend to be larger, more numerous, and more symptomatic (Kjerulff et al., 1996; Marshall et al., 1997; Baird et al., 2003) . Twin studies have shown that the concordance of hospitalization due to uterine fibroids or hysterectomy was significantly higher in monozygous twins compared to dizygous twins, providing further support for a genetic predisposition (Treloar et al., 1992; Gross and Morton, 2001) .
Several reports of the familial clustering of uterine fibroids demonstrated that fibroids were 4-5-fold more common in first degree relatives of women with leiomyoma, compared to the general population (Winkler and Hoffmann, 1938; Kurbanova et al., 1989; Vikhlyaeva et al., 1995; Schwartz et al., 2000) . Reed's syndrome, a rare inherited disorder, is characterized by the appearance of multiple leiomyomas in the skin, uterus, or both (Fisher and Helwig, 1963; Reed et al., 1973) . Recently, reports of several families in Finland and England with multiple uterine and cutaneous fibroids, and papillary renal cell carcinoma, were linked to mutations in the fumarate hydratase gene (Tomlinson et al., 2002) . In addition, mutations in the tuberous sclerosis 2 (TSC2) tumor suppressor gene leading to renal angiomyolipomas, cysts and carcinoma in humans are frequently associated with development of uterine leiomyomas in the Eker rat animal model (Walker et al., 2003) .
Cytogenetic studies have revealed that leiomyomas are monoclonal and , 40 -50% of uterine fibroids are reported to have nonrandom chromosomal abnormalities (Ligon and Morton, 2001) . Common cytogenetic changes include translocation between chromosomes 12 and 14 (20%), deletions in chromosome 7 (17%), trisomy of chromosome 12 (12%), and aberrations of chromosome 6 (5%) (Nilbert and Heim, 1990; Ligon and Morton, 2001; Flake et al., 2003) . Based on the results of cytogenetic studies, several gene candidates have been proposed to be involved in the development of uterine leiomyoma. The potential candidates included high mobility group (HMG) genes on chromosomes 12q15 and 6p21, estrogen receptor beta (ESR2) on chromosome 14q22, and RAD51L1 gene on chromosome 14q23 (Nilbert and Heim, 1990; Ligon and Morton, 2001) . HMG genes (HMGA1 and HMGA2) code for DNA-binding proteins that can induce conformational changes in DNA, thereby indirectly regulating transcription by influencing the access of other DNAbinding proteins to target genes. RAD51L1 is a member of the RAD51 recombination repair gene family and preferential fusion partner of HMGA2 in uterine leiomyoma (Takahashi et al., 2001) . In order to identify other critical genes and potential pathways involved in uterine leiomyoma, several studies have utilized the cDNA microarray screening methods.
Microarray studies of uterine leiomyoma
Previously, at least nine studies have examined the differential gene expression between uterine leiomyoma and normal myometrium using microarray analysis (Tsibris et al., 2002; Ahn et al., 2003; Catherino et al., 2003; Chegini et al., 2003b; Wang et al., 2003; Weston et al., 2003; Skubitz and Skubitz, 2003; Hoffman et al., 2004; Quade et al., 2004) . Tsibris et al. (2002) have studied the leiomyoma samples and matched myometrium from nine patients (five AfricanAmerican, two Caucasians, one Hispanic, one other ethnicity) in the proliferative and secretory phases of the menstrual cycle using the HUGeneFL6800 microarray chip (6800 genes per array) and the Affymetrixe U95A GeneChip (12 000 genes per array). In the combined analyses, 67 genes were up-regulated and 78 genes were down-regulated by . 2-fold in leiomyoma compared to matched myometrium. Chegini et al. (2003b) used the Clonteche Atlas microarray of 1176 cancer-related genes to study differential gene expression in the leiomyoma and matched normal myometrium from six patients: three untreated women and three women after GnRH analogue therapy. A total of 100 genes were differentially expressed, 18 up-regulated and 82 downregulated in untreated leiomyoma compared with normal myometrium. After GnRH analogue treatment, the expression of 34 genes showed a significant decrease in leiomyoma, whereas 27 genes increased and 15 decreased in myometrium compared with their respective untreated tissues. The differentially expressed genes are involved in regulation of cell cycle and growth, signal transduction, transcription factors, and cell structure, although no fold changes were reported (Chegini et al., 2003b) .
Weston et al. used in-house prepared microarrays of 10 500 human cDNA sequences to compare gene expression between leiomyoma/myometrium pairs from 12 hysterectomy specimens. Twenty-five differentially expressed genes were identified (14 up-regulated, 11 down-regulated) in leiomyoma compared to the adjacent myometrium. Several genes were confirmed by RT -PCR including overexpressed genes (IGF2, ETRA, COL4A2) and underexpressed angiogenesisrelated genes (CTGF, CYR61) (Weston et al., 2003) . Wang et al. (2003) have analysed the leiomyoma and adjacent myometrium obtained from seven patients during the proliferative phase of the menstrual cycle using the HUGeneFL6800 microarrays. A comparison of expression patterns in each paired sample revealed 68 genes significantly different in each paired tissue sample (23 overexpressed and 45 underexpressed genes) (Wang et al., 2003) . Skubitz and Skubitz (2003) have compared 20 uterine leiomyoma samples with 46 normal myometrial samples and 18 other tissues using the Affymetrixe U95 GeneChip, containing , 12 000 genes and , 48 000 expressed sequence tags (EST). Ninety-six known gene fragments (comprising 78 independent genes) and 149 EST were overexpressed at least two-fold and 358 gene fragments/EST were underexpressed $ 2-fold in the leiomyoma compared to normal myometrium (Skubitz and Skubitz, 2003) . Ahn et al. (2003) have screened up to 17 000 genes in leiomyoma and myometrium samples of six Korean patients using the GeneTrack Human cDNA HSVC 307 chip (Genomictree, Inc., Korea). A total of 71 differentially expressed genes (21 up-regulated and 50 down-regulated) were identified in this study (Ahn et al., 2003) .
Catherino et al. reported microarray analysis of up to 33 000 genes using the Affymetrixe U133 platform (Catherino et al., 2003) . Real time RT -PCR, Western blot, and immunohistochemistry were used to confirm the concordant mRNA and protein overexpression of FZD2 and CD24 but did not confirm DLK overexpression in five patients with leiomyoma. Subsequently, three commonly overexpressed genes (IGF2, CRABP2, CD24) and five underexpressed genes (ADH1, DPT, ATF3, ABCA, PTGER3) were reported by this study (Catherino et al., 2004a) .
Quade et al. reported results of microarray analyses of about 7000 gene probes using Affymetrix HuFl GeneChips in four normal uterine myometria, seven uterine leiomyomas, and nine uterine leiomyosarcomas. A total of 153 probe sets representing 146 unique genes were selected by analysis of variance and included in the cluster analysis, which suggested that the molecular pathways in leiomyoma and leiomyosarcoma are distinct (Quade et al., 2004) .
In a recent study, Hoffman et al. have compared tissues of normal myometrium and uterine leiomyoma from eight patients of varying age and race undergoing surgery for symptomatic fibroids. Using Affymetrix U133A GeneChip microarrays, 226 genes were found to be dysregulated by a^1.5-fold change between leiomyoma and normal myometrium. The authors identified several apoptosis-related genes, of particular interest were TRAIL and Ask1/MAP3K5, as well as several proliferation-related genes, including TGFB1, PDGFC, and two dual specificity phosphatases (Hoffman et al., 2004) .
We also have conducted a study to compare the expression of more than 22,000 genes between uterine leiomyoma and normal myometrium, as described below.
Materials and methods

Tissue samples
Study procedures and protocol were approved by the New York University School of Medicine (NYUSM) Institutional Board of Research Associates. Uterine tissue samples were obtained during the proliferative phase of the menstrual cycle from three women of different ethnic backgrounds (one African-American, one Caucasian, and one Hispanic) undergoing scheduled hysterectomy procedures. Patients in the study had the following characteristics: age (37, 49 and 47 years respectively), body mass index (35, 28 and 30 kg/m 2 respectively), and tumor size (10, 5 and 2 cm respectively). Phase of menstrual cycle was estimated using the date of the first day of the last menstrual period. After histopathological confirmation, the fresh-frozen tissue samples of leiomyoma and matched normal myometrial tissues were identified, dissected to ,0.5 cm in thickness, placed in 5 volumes of RNAlatere tissue storage/RNA stabilization solution (Ambion, USA) and transferred without personal identifiers to the NYU School of Medicine Molecular Biology Laboratory for gene expression analyses of 22 283 genes/ESTs using Affymetrixe Human Genome U133A microarray GeneChip w (Affymetrix, USA).
Gene expression analysis RNA was isolated from each sample using the Qiagen RNeasy Mini kit (Qiagen, Inc., USA). Sample preparation, hybridization and the array wash procedure were performed as described in the standard protocol provided by Affymetrixe. In brief, 10 mg total RNA from each sample were used to synthesize double-stranded cDNA with the Superscript Choice System (Invitrogen). The cDNA was used as a template to generate biotinylated cRNA by an in vitro transcription reaction. RNA quality was checked by analysis of the 3 0 :5 0 ratios for human actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) oligonucleotides on Affymetrixe Test 3 chips. Fifteen micrograms of cRNA from each sample were added to the U133A array. The hybridization was carried out at 45 8C for 16 h in the Affymetrixe Hybridization Oven. After sample hybridization, the microarrays were washed and stained with a steptavidin-conjugated fluorescent stain followed by antibody amplification on the Affymetrixe Fluidics Station 400. Each microarray was scanned twice. The first scanning was performed after steptavidin-conjugated fluorescent staining and the data were used for analyzing expression levels of abundant RNA. The array was scanned again after the whole washing and staining procedure was complete. The expression levels of genes were measured using GeneChip software version 4.01.
Data analysis
The raw data from array scans were normalized by median-centering genes for each array, and log transformed. Additionally, genes with 50% or more of 'absent' scores were filtered out. The remaining 9673 genes were analysed. To identify genes that are differentially expressed in leiomyoma samples compared to normal myometrium, the significance analysis of microarrays (SAM) method was used (Tusher et al., 2001) . SAM uses a modified t-test statistic with sample-label permutations to estimate the false discovery rate (FDR). The FDR is defined as the expected proportion of false discoveries among the genes that are declared significant (Benjamini and Hochberg, 1995; Storey, 2002; Storey and Tibshirani, 2003) . The FDR is used to determine the significance threshold for genes and to limit the likelihood of type I error taking into account the fact that thousands of genes are simultaneously being tested. In addition to the significance analysis of microarrays, foldchange analysis was performed, in which the ratios of geometric means of the expression intensities of the corresponding genes in leiomyoma samples relative to normal myometrium were calculated. The ratios were reported as the up-or down-fold change. To select the potentially important genes, we used threshold values of $ 2 and # -2 in the fold change between leiomyoma and normal myometrium and the FDR significance level of , 5%.
To compare the data on gene expression provided by different microarray studies of uterine leiomyoma, we have carefully examined the published lists of differentially expressed genes and identified the overlapping genes in two or more separate studies.
Results
Gene expression analysis of our data showed statistically significant average differences of $ 2-fold for 176 genes, 37 with increased expression and 139 with decreased expression in leiomyoma compared with normal myometrium. Of these, 80 unique genes had FDR of , 5%, 14 overexpressed and 66 underexpressed. Table I presents the 14 genes up-regulated, on average, by more than two-fold (FDR , 5%) in leiomyoma relative to matched myometrium in the three patients. The up-regulated genes included growth factors (IGF2, MEST, NEGF2), factors involved in extracellular matrix formation (MMP11, CSPG2), factors involved in angiogenesis (TMSNB, SFRP1), and genes involved in cell differentiation and metabolism (CD24, HTR2B, QPRT, GAGEC1, PTK7, PEMT). Table II shows 66 genes down-regulated, on average, by more than two-fold in leiomyoma compared to matched myometrium and with FDR , 5%. Prominent among the underexpressed genes were factors involved in retinoic acid metabolism (ADH1), and in TGF-b signaling (DPT), genes encoding several IGF-binding proteins (IGFBP6, CYR61/IGFBP10, NOV, CRIM1, CTGF), and mast cell enzymes (TPSB2 and CPA3). Transcripts involved in cytoskeletal integrity (FY, EMP1, TM4SF1, GPM6A, ITM2A, CAV2, SPG20, PLEC1, TUBGCP3) and cell adhesion (DPT, SELE, EFEMP1, S100A4, S100A6, SRPX, DCL1, PECAM1) were substantially down-regulated in uterine leiomyoma compared with matched normal myometrium suggesting significant changes in smooth muscle cell differentiation in leiomyoma (Table II) .
Genes up-regulated in leiomyoma
Genes down-regulated in leiomyoma
Overlapping genes in different microarray studies of leiomyoma
We compared our results with previously published microarray data and the concordant (up-regulated and down-regulated) genes reported by two or more different studies are listed in Table III . Two studies (Chegini et al., 2003b; Weston et al., 2003) were not included in Table III because they did not report the fold change between leiomyoma and myometrium. Despite the substantial variations in patients' characteristics (race/ethnicity, phase of menstrual cycle, age), gene array methodology (at least six different gene arrays platforms), and differences in statistical methods and data presentation, 71 genes (28 overexpressed and 43 underexpressed in leiomyoma compared to normal myometrium) were identified by at least two separate studies. They included eight prominent genes (ADH1, ATF3, CRABP2, CYR61, DPT, GRIA2, IGF2, MEST) identified by at least five different studies, 11 genes (ALDH1, CD24, CTGF, DCX, DUSP1, FOS, GAGEC1, IGFBP6, PTGDS, PTGER3, TYMS) reported by four studies, twelve genes (ABCA, ANXA1, APM2, CCL21, CDKN1A, CRMP1, EMP1, ESR1, FY, MAP3K5, TGFBR2, TIMP3) identified by three studies, and 40 genes reported by two different studies (Table III) .
Discussion
Although experimental and clinical evidence strongly suggests that leiomyoma growth is steroid hormone-dependent (Walker, 2002) , one of the surprising findings of the microarray studies was the lack of significant changes in estrogen receptors (except a moderate increase in ESR1 reported by three studies), progesterone receptors, or their nuclear receptor cofactors. A possible explanation is that steroid hormones may act through their target genes, which mediate hormonal effects (Catherino et al., 2004a) . One set of such estrogen-dependent genes suggested by microarray studies might be genes involved in retinoic acid metabolism.
Genes associated with retinoid metabolism
In agreement with our results, significant underexpression of ADH1 and ALDH1 in uterine leiomyoma compared to normal myometrium was one of the most common observations of gene array studies to date (Tsibris et al., 2002; Wang et al., 2003; Skubitz and Skubitz, 2003; Ahn et al., 2003; Catherino et al., 2003; Catherino et al., 2004a; Quade et al., 2004; Hoffman et al., 2004) . ADH1 and ALDH1 oxidize retinol to retinaldehyde and retinaldehyde to retinoic acid, respectively. Retinoic acid functions as a ligand controlling nuclear retinoic acid receptor (RAR) and retinoid X receptor (RXR) signaling pathways (Pfahl and Chytil, 1996; Napoli, 1999) .
Direct measurements of tissue levels of all-trans retinoic acid were shown to be increased in leiomyoma compared to normal myometrium, but only in the proliferative phase of the cycle (Tsibris et al., 1999) . This may be a result of estrogen-dependent up-regulation of short-chain retinol dehydrogenase (RODH) (Napoli, 2001; Rexer and Ong, 2002) , which is also overexpressed in uterine leiomyoma (Tsibris et al., 2002; Skubitz and Skubitz, 2003) .
Down-regulation of class I ADH may result either in response to increased levels of all-trans RA in leiomyoma cells by negative feed-back mechanism or via overexpression of high-mobility group (HMGA1, HMGA2) genes (Figure 1 ). HMGA1 and HMGA2 are located respectively, on chromosomes 6p21 and 12q15, which are commonly rearranged in leiomyoma and in a variety of other mesenchymal tumours (Reeves, 2000) . HMG proteins competitively bind to ADH class I HNF-1/HMGI promoter, affecting ADH1 gene transcription (Edenberg, 2000) .
A substantial increase in cellular retinoic acid binding proteins CRABP1 (Wu et al., 2002) and, particularly, CRABP2 (Tsibris et al., 2002; Wang et al., 2003; Skubitz and Skubitz, 2003; Catherino et al., 2004a; Hoffman et al., 2004) was another common observation from gene array studies. CRABP2 may have a role in the transfer of RA to its nuclear receptors and regulation of transcriptional activity of RAR and RXR (Dong et al., 1999; Delva et al., 1999; Budhu et al., 2001) . It has been shown in an animal model that CRABP2 gene expression in the uterus is directly induced by estrogens, but not retinoic acid (Li and Ong, 2003) . Tsibris et al. had shown that human leiomyoma express higher levels of all-trans RA, RXR, and PPARg, and that sustained exposures to estrogen, PPARg ligand (troglitazone) and all-trans RA were required for uterine leiomyoma growth in guinea pig in vivo model (Tsibris et al., 1999) . Based on available data, we conclude that in uterine leiomyoma there is a co-requirement of increased estrogens (via aromatase) and retinoic acid (via up-regulated retinol/retinaldehyde dehydrogenase) that sustains tumour growth.
Genes related to growth and proliferation
Up-regulation of IGF2 is one of the most consistent observations of gene array studies to date (Table III) . IGF2 acts mainly through the IGF receptor type I (IGF1R), whereas IGF receptor type II (IGF2R) is involved with IGF2 degradation. Previously, IGF2 mRNA, but not its receptor levels, had been reported to be higher in the leiomyoma tissues compared to the myometrium (Hoppener et al., 1988; Boehm et al., 1990; Vollenhoven et al., 1993) . Similar to IGF1, IGF2 is involved in proliferation, differentiation, and transformation in a wide variety of cell types. Effects of IGF2 are modulated by IGF-binding proteins (Stewart and Rotwein, 1996) . Six IGFBP with high affinity for IGFs have been identified and an additional four IGFBP-related proteins have been described (Kim et al., 1997; Hwa et al., 1999) . Interestingly, we and at least six other groups observed that genes encoding several IGF-binding proteins were significantly down-regulated in leiomyoma compared to normal myometrium, including IGFBP6 (Tsibris et al., 2002; Skubitz and Skubitz, 2003; Hoffman et al., 2004) , CYR61/IGFBP10 (Sampath et al., 2001; Tsibris et al., 2002; Weston et al., 2003; Ahn et al., 2003; Hoffman et al., 2004; Quade et al., 2004) , and CTGF (Ahn et al., 2003; Weston et al., 2003; Hoffman et al., 2004) .
IGFBP6 is of particular interest because its affinity for IGF2 is 20-100-fold greater than that for IGF1 (Roghani et al., 1991; Bach, 1999) indicating that it may serve as IGF2-specific binding protein, modulating IGF2 action. IGFBP6 expression is stimulated by all-trans RA in every cell model investigated thus far (Sheikh et al., 1993; Martin et al., 1994; Zhou et al., 1996; Babajko and Binoux, 1996; Gabbitas and Canalis, 1996; Chambery et al., 1998; Sueoka et al., 2000; Kim et al., 2002) , while stromelysin 3 (MMP11) degrades IGFBPs (Fowlkes et al., 1999) . Therefore, substantial down-regulation of IGFBP6, as a result of decreased retinoid signaling or increased MMP11 expression, may lead to an increased bioavailability of IGF2 and further activation of the IGF2 autocrine loop, promoting growth of uterine leiomyoma.
In addition, some of the effects of RA may be independent of the action via the RAR and RXR nuclear receptors and involve direct binding to the IGF2R leading to an intracellular redistribution of the IGF2R and lysosomal enzymes (Kang et al., 1997 , Kang et al., 1998 . Several studies have suggested that IGF2R is a tumor suppressor gene, which loss or mutation thereof had been implicated in various tumors (De Souza et al., 1995; Hankins et al., 1996; Ouyang et al., 1997; Xu et al., 1997) . We hypothesize that reduction or loss of IGF2R and reduced expression of IGFBPs with high affinity to IGF2, may lead to overexpression of IGF2 and uterine leiomyoma growth. Figure 1 illustrates a potential pathway of uterine leiomyoma development based on the data generated by the gene array studies. The most common findings suggest that interaction between the retinoid-related genes (RODH, ADH1, ALDH1, CRABP2) and IGF metabolism-related genes (IGF2, IGFBP6, CYR61/IGFBP10, MMP11) may play a significant role in uterine leiomyoma development.
Genes associated with differentiation
Leiomyoma cells are characterized by profound changes in cell differentiation. CD24 is commonly expressed by lymphoid cells, neuroblasts, certain cancer cells, as well as by regenerating muscle (Figarella-Branger et al., 1993) and had been correlated with a poor state of cell differentiation (Huang and Hsu, 1995; Catherino et al., 2004a) . CD24 and its signal transducer (CD24ST) have been consistently reported to be up-regulated in uterine leiomyoma (Tsibris et al., 2002; Catherino et al., 2003; Skubitz and Skubitz, 2003; Weston et al., 2003) . It has been proposed that CD24 overexpression is an important marker of a fundamental alteration in leiomyoma cell differentiation (Catherino et al., 2004a) .
Prominent among consistently up-regulated genes in the different studies were doublecortin (Tsibris et al., 2002; Ahn et al., 2003; Skubitz and Skubitz, 2003; Weston et al., 2003; Hoffman et al., 2004) and ionotropic glutamate receptor 2 (Tsibris et al., 2002; Skubitz and Skubitz, 2003; Wang et al., 2003; Weston et al., 2003; Hoffman et al., 2004; Quade et al., 2004) . Doublecortin (DCX) was originally identified in studies of patients with defective cortical neuronal migration (lissencephaly) (des Portes et al., 1998; Gleeson et al., 1998) . DCX functions as a microtubule-associated protein and contains two internal tandem repeats. While each repeat separately binds tubulin, both are required to bind concomitantly for microtubule polymerization (Taylor et al., 2000) .
Ionotropic glutamate receptor 2 (GRIA2) is a subunit of a ligand-gated cation channel and has been reported to be overexpressed in leiomyoma relative to myometrium up to 30-fold (Tsibris et al., 2002; Skubitz and Skubitz, 2003; Wang et al., 2003; Weston et al., 2003; Hoffman et al., 2004; Quade et al., 2004) . GRIA2 may play a role in local angiogenesis by increasing Ca 2þ influx into leiomyoma and supporting vascularization . In leiomyoma, a synergism between increased production of estradiol and all-trans retinoic acid with up-regulation of nuclear receptors PPARg and RXR had been proposed (Tsibris et al., 1999) . GRIA2 might be coupled to this synergism directly or via interleukin 17 (IL17) and kinesin family 5 (KIF5C) genes , both of which had been reported to be up-regulated in leiomyoma (Ahn et al., 2003; Skubitz and Skubitz, 2003; Tsibris et al., 2003) .
Among consistently down-regulated genes in leiomyoma were tryptase beta 2 (TPSB2) and carboxypeptidase A3 (CPA3), which are enzymes produced by mast cells. Decreased expression of these enzymes is consistent with a less differentiated state and may indicate a reduction in the number or function of mast cells in uterine leiomyoma, as previously suggested (Tsibris et al., 2002) .
Other commonly down-regulated groups of genes include transcription factors (ATF3, GATA2, JUN, FOS), factors involved in lipid metabolism (APM2, ABCA, APOD), cell integrity proteins (KRT19, ABLIM, EFEMP1, FY, EMP1), nucleic acid metabolism (GBP2, RNASE4), and complement factors (CFH, C7) (Table III) .
Genes related to the extracellular matrix
Extracellular matrix is thought to play an important role in the pathophysiology of uterine leiomyoma (Sozen and Arici, 2002) . Overproduction of the ECM proteins contributes extensively to leiomyoma volume expansion. ECM is composed predominantly of collagens, proteoglycans, and matrix glycoproteins. In addition to its role in cell shape, proliferation, and differentiation, ECM serves as a repository for growth factors and cytokines and mediates their activation and turnover (Sozen and Arici, 2002) . (HMGA1, HMGA2) , may lead to substantial underexpression of enzymes involved in retinoid synthesis and cell differentiation (ADH1 and ALDH1). All-trans RA induces TGF-b3, leading to further activation of CRABP2, as well as overexpression of stromelysin 3 (MMP11), which degrades IGF-binding proteins (IGFBP6, CYR61/IGFBP10). This may result in increased local bioavailability and overexpression of IGFs, particularly IGF2, which via IGF1R may lead to increased proliferation and decreased apoptosis, thereby promoting the growth of uterine leiomyoma.
Differential gene expression in uterine leiomyoma
The proteoglycan, dermatopontin (DPT), was one of the most commonly down-regulated genes in our and previous gene array studies (Tsibris et al., 2002; Ahn et al., 2003; Wang et al., 2003; Catherino et al., 2004a,b) . DPT interacts with decorin for TGF-b binding and plays an important role in cell-matrix interactions and matrix assembly (Kuroda et al., 1999; Okamoto et al., 1999) . It has been proposed that down-regulation of DPT would indirectly increase decorin function, leading to disruption of the processing of collagen fibrils (Ichii et al., 2001; Catherino et al., 2004b) and activation of TGF-b signaling pathway (Riquelme et al., 2001) . Factors decreasing the expression of DPT include collagen type I (Kuroda et al., 1999) , which had been shown to be overexpressed in leiomyoma (Stewart et al., 1994) . Reduction of DPT and increased TGF-b3 signalling have been proposed as a molecular link between uterine leiomyoma and keloid formation (Catherino et al., 2004b) .
The TGF-b3-coding gene is located near the 14q23-24 break-point, which is one of the most common translocation sites reported by cytogenetic studies of uterine fibroids (Andersen, 1998) . Compared to normal myometrium, TGFb3 expression is 3.5 -5-fold higher in leiomyoma (Arici and Sozen, 2000; Lee and Nowak, 2001; Tsibris et al., 2002; Quade et al., 2004) . In addition, the expression of SMAD-3 and -4, intracellular proteins that transmit TGF-b receptor signals, is increased in leiomyoma compared to normal myometrium (Chegini et al., 2003a) . TGF-b proteins are potent inducers of collagens I, III and fibronectin (Ignotz and Massague, 1986) . Extracellular matrix is regulated by the combined action of matrix metalloproteinases (MMP) and their inhibitors, tissue inhibitors of MMPs (TIMPs). It has been shown that both leiomyoma and myometrium express higher levels of MMP and TIMP mRNA during the secretory phase of the cycle compared to the proliferative phase, suggesting that MMP and TIMP expression in leiomyoma and myometrium are hormonally regulated (Dou et al., 1997) . Palmer et al. have shown that the levels of MMP1 and MMP3 mRNA were similar in leiomyoma and myometrium, whereas stromelysin 3 (MMP11) was significantly elevated in uterine leiomyoma suggesting that stromelysin 3 may be involved in the formation of more fibrous extracellular matrix compared to unaffected myometrium (Palmer et al., 1998) . Figure 2 shows the potential relationships between TGFb3, induction of collagens types I, III, and IV and downregulation of dermatopontin (DPT). In this model, TGF-b overexpression may induce tissue inhibitor of metalloproteinase (TIMP1) (Ma and Chegini, 1999) , thus shifting MMP/TIMP balance and further promoting matrix accumulation.
Platelet-derived growth factor (PDGF) may act as a potential mediator of TGF-b effects in smooth muscle cells (Janat and Liau, 1992; Nishio and Watanabe, 1997; Arici and Sozen, 2003) . PDGF up-regulates expression of the ECM proteoglycan versican (CSPG2) by smooth muscle cells (Evanko et al., 2001) and, by itself, is a potent mitogen that can bind to heparin and be sequestered in the ECM to exert its functions (Nowak, 1999) .
TGF-b3 and MMP11 may represent the common molecules shared by the pathways described in Figures 1 and 2 . The proposed pathways point to an important role of the extracellular matrix expansion in uterine leiomyoma. We hypothesize that the ECM accumulation and shift in MMP/TIMP balance may in part explain such key features of leiomyoma as local expansion and lack of invasion.
In summary, despite the substantial differences in patients' characteristics, laboratory methods and analytical approaches, the results from gene expression studies point to several Figure 2 . Potential pathway of uterine leiomyoma development involving TGF-b3 activation and extracellular matrix formation. TGF-b3 induces the formation of fibronectin and collagen types I, III, and IV. Collagen type I down-regulates dermatopontin (DPT) expression which may result in further activation of the TGF-b3-signaling pathway in smooth muscle cells. TGF-b3 overexpression leads to up-regulation of stromelysin 3 (MMP11) and tissue inhibitor of metalloproteinase (TIMP1), leading to accumulation of extracellular matrix proteins. Plateletderived growth factor (PDGF) may act as a mediator of TGF-b effects in smooth muscle cells. In addition to its mitogenic and anti-apoptotic properties, PDGF up-regulates proteoglycan versican (CSPG2) expression, contributing to the expansion of the extracellular matrix, commonly observed in uterine leiomyoma. themes essential for uterine leiomyoma development. The consistently observed changes in genes regulating retinoid synthesis, IGF-II metabolism, TGF-b signaling and ECM formation indicate the potential importance of these factors in the development of leiomyoma. Ongoing and future research should clarify whether the commonly observed changes in gene expression correspond to protein alterations in uterine leiomyoma. Understanding the common molecular pathways of uterine leiomyoma initiation and progression is critical for development of novel strategies for treatment and prevention of this common condition.
